BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37610864)

  • 1. A Prognostic Model for Prostate Cancer Patients Based on Two DNA Damage Response Mutation-Related Immune Genes.
    Wang J; Jiang L; Shang Z; Ye Z; Yuan D; Cui X
    Cancer Biother Radiopharm; 2024 May; 39(4):306-317. PubMed ID: 37610864
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of ISG15 and ZFP36 as novel hypoxia- and immune-related gene signatures contributing to a new perspective for the treatment of prostate cancer by bioinformatics and experimental verification.
    Lyu F; Li Y; Yan Z; He Q; Cheng L; Zhang P; Liu B; Liu C; Song Y; Xing Y
    J Transl Med; 2022 May; 20(1):202. PubMed ID: 35538543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
    Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
    Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a Four Cancer Stem Cell-Related Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Adenocarcinoma.
    Li S; Chen R; Luo W; Lin J; Chen Y; Wang Z; Lin W; Li B; Wang J; Yang J
    Comb Chem High Throughput Screen; 2022; 25(12):2070-2081. PubMed ID: 35048799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer.
    Li H; Gu J; Tian Y; Li S; Zhang H; Dai Z; Wang Z; Zhang N; Peng R
    Front Immunol; 2022; 13():982628. PubMed ID: 36325340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel six autophagy-related genes signature for the prognostic and a miRNA-related autophagy predictor for anti-PD-1 therapy responses in prostate cancer.
    Wu L; Quan W; Yue G; Luo Q; Peng D; Pan Y; Zhang G
    BMC Cancer; 2021 Jan; 21(1):15. PubMed ID: 33402116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel DNA damage repair-related gene signature predicting survival, immune infiltration and drug sensitivity in cervical cancer based on single cell sequencing.
    Xiang X; Kang J; Jiang J; Zhang Y; Zhang Y; Li L; Peng X
    Front Immunol; 2023; 14():1198391. PubMed ID: 37449209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derivation and Comprehensive Analysis of Aging Patterns in Patients with Bladder Cancer.
    Wang B; Tong F; Zhai C; Wang L; Liu Y; Wang J
    Dis Markers; 2021; 2021():3385058. PubMed ID: 34721733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.
    Feng D; Xiong Q; Zhang F; Shi X; Xu H; Wei W; Ai J; Yang L
    Front Immunol; 2022; 13():777724. PubMed ID: 35154101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
    Hu B; Zhang X; Zhu S; Wang C; Deng Z; Wang T; Wu Y
    Eur J Med Res; 2024 Jan; 29(1):92. PubMed ID: 38297388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer.
    Liu B; Li X; Li J; Jin H; Jia H; Ge X
    Dis Markers; 2020; 2020():8860788. PubMed ID: 33101546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
    Luo Y; Liu X; Lin J; Zhong W; Chen Q
    Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexpression Network Analysis Identifies a Novel Nine-RNA Signature to Improve Prognostic Prediction for Prostate Cancer Patients.
    Cai J; Chen Z; Chen X; Huang H; Lin X; Miao B
    Biomed Res Int; 2020; 2020():4264291. PubMed ID: 32953881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram.
    Rui X; Shao S; Wang L; Leng J
    BMC Cancer; 2019 Dec; 19(1):1179. PubMed ID: 31795990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Establishment of a prostate cancer prognostic risk model based on the TCGA database and inflammation-related genes].
    Zhong RF; Wu JC; Ling JC; Meng JL; Fan S
    Zhonghua Nan Ke Xue; 2022 Nov; 28(11):985-995. PubMed ID: 37846114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients.
    Zhang D; Xu X; Wei Y; Chen X; Li G; Lu Z; Zhang X; Ren X; Wang S; Qin C
    Cancer Control; 2022; 29():10732748221129451. PubMed ID: 36283420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.
    Zhao Y; Tao Z; Li L; Zheng J; Chen X
    BMC Cancer; 2022 Mar; 22(1):239. PubMed ID: 35246070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.